Last reviewed · How we verify

NCT03343899: GenVDisc

Genotype-related Molecular Targets in the Vitamin D Pathway for Spinal Disc Diseases

Status unknown Last updated 17 November 2017
What this trial tests

trial in Intervertebral Disk Degeneration in 15 participants. Status unknown.

Timeline
17 February 2016
Primary endpoint
17 February 2018
17 February 2019

Quick facts

Lead sponsorI.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment15
Start date17 February 2016
Primary completion17 February 2018
Estimated completion17 February 2019
Sites1 location across Italy

Conditions studied

Sponsor

I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio — full company profile →

Who can join

Adults 18 to 70, any sex, with Intervertebral Disk Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of our study will be to analyze the interplay between particular VDR variants and its ligand in cells obtained from intervertebral disc and cartilage endplate and their action on cell proliferation and phenotype maintenance. The identification of novel molecular targets in the vitamin D pathway, potentially promoting pathological alterations of the tissues involved in spinal disc diseases, will allow to develop innovative and more personalized preventive and pharmacological/nutritional therapies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03343899.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing